References

Aird WC. Endothelial cell heterogeneity. Crit Care Med 31:S221-S230, 2003.

Aird WC, Edelberg JM, Weiler-Guettler H, Simmons WW, Smith TW, Rosenberg RD. Vascular bed-specific expression of an endothelial cell gene is programmed by the tissue microenvironment. J Cell Biol 138:1117-1124, 1997.

Amiral J, Wolf M, Fischer A, Boyer-Neumann C, Vissac A, Meyer D. Pathogenicity of IgA and/or IgM antibodies to heparin-PF4 complexes in patients with heparin-induced thrombocytopenia. Br J Haematol 92:954-959, 1996.

Arepally GM, Kamei S, Park KS, Kamei K, Li ZQ, Liu W, Siegel DL, Kisiel W, Cines DB, Poncz M. Characterization of a murine monoclonal antibody that mimics heparin-induced thrombocytopenia antibodies. Blood 95:1533-1540, 2000.

Arepally GM, Mayer IM. Antibodies from patients with heparin-induced thrombocyto-penia stimulate monocytic cells to express tissue factor and secrete interleukin-8. Blood 98:1252-1254, 2001.

Barber AJ, Käser-Glanzmann R, Jakabova M, Lüscher EF. Characterization of a chondroitin 4-sulfate proteoglycan carrier for heparin neutralizing activity (platelet factor 4) released from human blood platelets. Biochim Biophys Acta 286:312-329, 1972.

Basta G, Schmidt AM, De Caterina R. Advanced glycation end products and vascular inflammation: implications for accelerated atherosclerosis in diabetes. Cardiovasc Res 63:582-592, 2004.

Bauer TL, Arepally G, Konkle BA, Mestichelli B, Shapiro SS, Cines DB, Poncz M, McNulty S, Amiral J, Hauck WW, Edie RN, Mannion JD. Prevalence of heparin-associated antibodies without thrombosis in patients undergoing cardiopulmonary bypass surgery. Circulation 95:1242-1246, 1997.

Benezra M, Vlodavsky I, Ishai-Michaeli R, Neufeld G, Bar-Shavit R. Thrombin-induced release of active basic fibroblast growth factor- heparan sulfate complexes from subendothelial extracellular matrix. Blood 81:3324-3331, 1993.

Blank M, Cines DB, Arepally G, Eldor A, Afek A, Shoenfeld Y. Pathogenicity of human anti-platelet factor 4 (PF4)/heparin in vivo: generation of mouse anti-PF4/heparin and induction of thrombocytopenia by heparin. Clin Exp Immunol 108:333-339, 1997.

Blank M, Shoenfeld Y, Tavor S, Praprotnik S, Boffa MC, Weksler B, Walenga MJ, Amiral J, Eldor A. Anti-platelet factor 4/heparin antibodies from patients with heparin-induced thrombocytopenia provoke direct activation of microvascular endothelial cells. Int Immunol 14:121-129, 2002.

Bock PE, Luscombe M, Marshall SE, Pepper DS, Holbrook JJ. The multiple complexes formed by the interaction of platelet factor 4 with heparin. Biochem J 191:769-776, 1980.

Bordron A, Revelen R, D'Arbonneau F, Dueymes M, Renaudineau Y, Jamin C, Youinou P. Functional heterogeneity of anti-endothelial cell antibodies. Clin Exp Immunol 124:492-501, 2001.

Busch C, Dawes J, Pepper DS, Wasteson A. Binding of platelet factor 4 to cultured human umbilical vein endothelial cells. Thromb Res 19:129-137, 1980.

Cesarman-Maus G, Ríos-Luna NP, Deora AB, Huang B, Villa R, Cravioto MdC, Alarcón-Segovia D, Sánchez-Guerrero J, Hajjar KA. Autoantibodies against the fibrinolytic receptor, annexin 2, in antiphospholipid syndrome. Blood 107:4375-4382, 2006.

Cines DB, Tomaski A, Tannenbaum S. Immune endothelial-cell injury in heparin-associated thrombocytopenia. N Engl J Med 316:581-589,1987.

Cines DB, Pollak ES, Buck CA, Loscalzo J, Zimmerman GA, McEver RP, Pober JS, Wick TM, Konkle BA, Schwartz BS, Barnathan ES, McCrae KR, Hug BA, Schmidt AM, Stern DM. Endothelial cells in physiology and pathophysiology of vascular disorders. Blood 91:3527-3561, 1998.

Constans J, Dupuy R, Blann AD, Resplandy F, Seigneur M, Renard M, Longy-Boursier M, Schaeverbeke T, Guerin V, Boisseau MR, Conri C. Anti-endothelial cell auto-antibodies and soluble markers of endothelial cell dysfunction in systemic lupus erythematosus. J Rheumatol 30:1963-1966, 2003.

David G, Bai XM, Van der Schueren B, Cassiman JJ, Van den Berghe H. Developmental changes in heparan sulfate expression: in situ detection with mAbs. J Cell Biol 119:961-975, 1992.

Dawes J, Pumphrey CW, McLaren KM, Prowse CV, Pepper DS. The in vivo release of human platelet factor 4 by heparin. Thromb Res 27:65-76, 1982.

Del Papa N, Guidali L, Sala A, Buccellati C, Khamashta MA, Ichikawa K, Koike T, Balestrieri G, Tincani A, Hughes GR, Meroni PL. Endothelial cells as target for antiphospholipid antibodies. Human polyclonal and monoclonal anti-ß2-glyco-protein I antibodies react in vitro with endothelial cells through adherent ß2-glycoprotein I and induce endothelial activation. Arthritis Rheum 40:551-561, 1997.

Denomme GA, Warkentin TE, Horsewood P, Sheppard JA, Warner MN, Kelton JG. Activation of platelets by sera containing IgG1 heparin-dependent antibodies: an explanation for the predominance of the FcgRIIa "low responder" (his131) gene in patients with heparin-induced thrombocytopenia. J Lab Clin Med 130:278-284, 1997.

Diujvestijn AM, Derhaag JG, van Breda Vriesman PJ. Complement activation by anti-endothelial cell antibodies in MHC-mismatched and MHC-matched heart allograft rejection: anti-MHC-, but not anti non-MHC alloantibodies are effective in complement activation. Transpl Int 13:363-371, 2000.

Drake TA, Cheng J, Chang A, Taylor FB, Jr. Expression of tissue factor, thrombomodu-lin, and E-selectin in baboons with lethal Escherichia coli sepsis. Am J Pathol 142:1458-1470, 1993.

Dudek AZ, Pennell CA, Decker TD, Young TA, Key NS, Slungaard A. Platelet factor 4 binds to glycanated forms of thrombomodulin and to protein C. A potential mechanism for enhancing generation of activated protein C. J Biol Chem 272: 31785-31792,1997.

Esko JD, Lindahl U. Molecular diversity of heparan sulfate. J Clin Invest 108:169-173, 2001.

Eslin DE, Zhang C, Samuels KJ, Rauova L, Zhai L, Niewiarowski S, Cines DB, Poncz M, Kowalska MA. Transgenic mice studies demonstrate a role for platelet factor 4 in thrombosis: dissociation between anticoagulant and antithrombotic effect of heparin. Blood 104:3173-3180, 2004.

Esmon CT. The roles of protein C and thrombomodulin in the regulation of blood coagulation. J Biol Chem 264:4743-4746,1989.

Esmon CT. Protein C anticoagulant pathway and its role in controlling microvascular thrombosis and inflammation. Crit Care Med 29(7 Suppl):S48-S51, 2001.

Forsberg E, Kjellen L. Heparan sulfate: lessons from knockout mice. J Clin Invest 108:175-180, 2001.

Fries JW, Williams AJ, Atkins RC, Newman W, Lipscomb MF, Collins T. Expression of VCAM-1 and E-selectin in an in vivo model of endothelial activation. Am J Pathol 143:725-737, 1993.

Fuster V, Poon M, Willerson JT. Learning from the transgenic mouse: endothelium, adhesive molecules, and neointimal formation. Circulation 97:16-18, 1998.

Ghiselli G, Lindahl U, Salmivirta M. Foam cell conversion of macrophages alters the biosynthesis of heparan sulfate. Biochem Biophys Res Commun 247:790-795, 1998.

Greinacher A, Pötzsch B, Amiral J, Dummel V, Eichner A, Mueller-Eckhardt C. Heparin-associated thrombocytopenia: isolation of the antibody and characterization of a multimolecular PF4-heparin complex as the major antigen. Thromb Haemost 71:247-251, 1994.

Greinacher A, Farner B, Kroll H, Kohlmann T, Warkentin TE, Eichler P. Clinical features of heparin-induced thrombocytopenia including risk factors for thrombosis. A retrospective analysis of 408 patients. Thromb Haemost 94:132-135, 2005.

HajMohammadi S, Enjyoji K, Princivalle M, Christi P, Lech M, Beeler D, Rayburn H, Schwartz JJ, Barzegar S, de Agostini AI, Post MJ, Rosenberg RD, Shworak NW. Normal levels of anticoagulant heparan sulfate are not essential for normal hemos-tasis. J Clin Invest 111:989-999, 2003.

Herbert JM, Savi P, Jeske WP, Walenga JM. Effect of SR121566A, a potent GP IIb-IIIa antagonist, on the HIT serum/heparin-induced platelet mediated activation of human endothelial cells. Thromb Haemost 80:326-331, 1998.

Huo Y, Schober A, Forlow SB, Smith DF, Hyman MC, Jung S, Littman DR, Weber C, Ley K. Circulating activated platelets exacerbate atherosclerosis in mice deficient in apolipoprotein E. Nature Med 9:61-67, 2003.

Isermann B, Hendrickson SB, Zogg M, Wing M, Cummiskey M, Kisanuki YY, Yanagisawa M, Weiler H. Endothelium-specific loss of murine thrombomodulin disrupts the protein C anticoagulant pathway and causes juvenile-onset thrombosis. J Clin Invest 108:537-546, 2001.

Jordan RE, Favreau LV, Braswell EH, Rosenberg RD. Heparin with two binding sites for antithrombin or platelet factor 4. J Biol Chem 257:400-406, 1982.

Kaplanski G, Marin V, Fabrigoule M, Boulay V, Benoliel AM, Bongrand P, Kaplanski S, Farnarier C. Thrombin-activated human endothelial cells support monocyte adhesion in vitro following expression of intercellular adhesion molecule-1 (ICAM-1; CD54) and vascular cell adhesion molecule-1 (VCAM-1; CD106). Blood 92:1259-1267,1998.

Khairy M, Lasne D, Brohard-Bohn B, Aiach M, Rendu F, Bachelot-Loza C. A new approach in the study of the molecular and cellular events implicated in heparin-induced thrombocytopenia. Thromb Haemost 85:1090-1096, 2001.

Kinsella MG, Wight TN. Modulation of sulfated proteoglycan synthesis by bovine aortic endothelial cells during migration. J Cell Biol 102:679-687, 1986.

Lasagni L, Francalanci M, Annunziata F, Lazzeri E, Giannini S, Cosmi L, Sagrinati C, Mazzinghi B, Orlando C, Maggi E, Marra F, Romagnani S, Serio M, Romagnani P. An alternatively spliced variant of CXCR3 mediates the inhibition of endothelial cell growth induced by IP-10, Mig, and I-TAC, and acts as functional receptor for platelet factor 4. J Exp Med 197:1537-1549, 2003.

Laszik Z, Mitro A, Taylor FB Jr, Ferrell G, Esmon CT. Human protein C receptor is present primarily on endothelium of large blood vessels: implications for the control of the protein C pathway. Circulation 96:3633-3640,1997.

Levin EG, del Zoppo GJ. Localization of tissue plasminogen activator in the endothelium of a limited number of vessels. Am J Pathol 144:855-861,1994.

Loscalzo J, Melnick B, Handin RI. The interaction of platelet factor four and glycosami-noglycans. Arch Biochem Biophys 240:446-455, 1985.

Lowe-Krentz LJ, Joyce JG. Venous and aortic porcine endothelial cells cultured under standardized conditions synthesize heparan sulfate chains which differ in charge. Anal Biochemistry 193:155-163, 1991.

Marcum JA, Rosenberg RD. Anticoagulantly active heparin-like molecules from vascular tissue. Biochem 23:1730-1737, 1984.

Marcum JA, McKenney JB, Rosenberg RD. Acceleration of thrombin-antithrombin complex formation in rat hindquarters via heparin-like molecules bound to the endothelium. J Clin Invest 74:341-350, 1984.

Meroni P, Ronda N, Raschi E, Borghi MO. Humoral autoimmunity against endothe-lium: theory or reality? Trends Immunol 26:275-281, 2005.

Meyer O, Aslan T, Koster A, Kiesewetter H, Salama A. Report of a patient with heparin-induced thrombocytopenia type II associated with IgA antibodies only. Clin Appl Thromb Hemost 12:373-375, 2006.

Nader HB, Buonassisi V, Colburn P, Dietrich CP. Heparin stimulates the synthesis and modifies the sulfation pattern of heparan sulfate proteoglycan from endothelial cells. J Cell Physiol 140:305-310, 1989.

Nassar T, Sachais BS, Akkawi S, Kowalska MA, Bdeir K, Leitersdorf E, Hiss E, Ziporen L, Aviram M, Cines D, Poncz M, Higazi AA. Platelet factor 4 enhances the binding of oxidized low-density lipoprotein to vascular wall cells. J Biol Chem 278: 6187-6193, 2003.

Nathan S, Ihrcke JLP. Shedding of heparan sulfate proteoglycan by stimulated endothelial cells: evidence for proteolysis of cell-surface molecules. J Cell Physiol 168:625-637, 1996.

Nishinaga M, Ozawa T, Shimada K. Homocysteine, a thrombogenic agent, suppresses anticoagulant heparan sulfate expression in cultured porcine aortic endothelial cells. J Clin Invest 92:1381-1386,1993.

Patton WA 2nd, Granzow CA, Getts LA, Thomas SC, Zotter LM, Gunzel KA, Lowe-Krentz LJ. Identification of a heparin-binding protein using monoclonal antibodies that block heparin binding to porcine aortic endothelial cells. Biochem J 311: 461-469, 1995.

Peiper SC, Wang ZX, Neote K, Martin AW, Showell HJ, Conklyn MJ, Ogborne K, Hadley TJ, Lu ZH, Hesselgesser J, Horuk R. The Duffy antigen/receptor for chemokines (DARC) is expressed in endothelial cells of Duffy negative individuals who lack the erythrocyte receptor. J Exp Med 181:1311-1317, 1995.

Pitsilos S, Hunt J, Mohler ER, Prabhakar AM, Poncz M, Dawicki J, Khalapyan TZ, Wolfe ML, Fairman R, Mitchell M, Carpenter J, Golden MA, Cines DB, Sachais BS. Platelet factor 4 localization in carotid atherosclerotic plaques: correlation with clinical parameters. Thromb Haemost 90:1112-1120, 2003.

Pouplard C, Iochmann S, Renard B, Herault O, Colombat P, Amiral J, Gruel Y. Induction of monocyte tissue factor expression by antibodies to heparin-platelet factor 4 complexes developed in heparin-induced thrombocytopenia. Blood 97: 3300-3302, 2001.

Praprotnik S, Blank M, Meroni PL, Rozman B, Eldor A, Shoenfeld Y. Classification of anti-endothelial cell antibodies into antibodies against microvascular and macrovas-cular endothelial cells: the pathogenic and diagnostic implications. Arthritis Rheum 44:1484-1494, 2001a.

Praprotnik S, Blank M, Levy Y, Tavor S, Boffa MC, Weksler B, Eldor A, Shoenfeld Y. Anti-endothelial cell antibodies from patients with thrombotic thrombocytopenic purpura specifically activate small vessel endothelial cells. Int Immunol 13:203-210, 2001b.

Rauova L, Poncz M, McKenzie SE, Reilly MP, Arepally G, Weisel JW, Nagaswami C, Cines DB, Sachais BS. Ultralarge complexes of PF4 and heparin are central to the pathogenesis of heparin-induced thrombocytopenia. Blood 105:131-138, 2005.

Rauova L, Zhai L, Kowalska MA, Arepally GM, Cines DB, Poncz M. Role of platelet surface PF4 antigenic complexes in heparin-induced thrombocytopenia pathogen-esis: diagnostic and therapeutic implications. Blood 107:2346-2353, 2006.

Reilly MP, Taylor SM, Hartman NK, Arepally GM, Sachais BS, Cines DB, Poncz M, McKenzie SE. Heparin-induced thrombocytopenia/thrombosis in a transgenic mouse model requires human platelet factor 4 and platelet activation through FcgRIIA. Blood 98:2442-2447, 2001.

Reilly MP, Taylor SM, Franklin C, Sachais BS, Cines DB, Williams KJ, McKenzie SE. Prothrombotic factors enhance heparin-induced thrombocytopenia and thrombosis in vivo in a mouse model. J Thromb Haemost 4:2687-2694, 2006.

Rosenberg RD, Shworak NW, Liu J, Schwartz JJ, Zhang L. Heparan sulfate proteogly-cans of the cardiovascular system. Specific structures emerge but how is synthesis regulated? J Clin Invest 99:2062-2070, 1997.

Rucinski B, Knight LC, Niewiarowski S. Clearance of human platelet factor 4 by liver and kidney: its alteration by heparin. Am J Physiol 251:H800-H807, 1986.

Rucinski B, Niewiarowski S, Strzyzewski M, Holt JC, Mayo KH. Human platelet factor 4 and its C-terminal peptides: heparin binding and clearance from the circulation. Thromb Haemost 63: 493-498, 1990.

Rybak ME, Gimbrone MA Jr, Davies PF, Handin RI. Interaction of platelet factor four with cultured vascular endothelial cells. Blood 73:1534-1539, 1989.

Saadi S, Platt JL. Transient perturbation of endothelial integrity induced by natural antibodies and complement. J Exp Med 181:21-31, 1995.

Saadi S, Holzknecht RA, Patte CP, Stern DM, Platt JL. Complement-mediated regulation of tissue factor activity in endothelium. J Exp Med 182:1807-1814, 1995.

Sachais BS, Kuo A, Nassar T, Morgan J, Kariko K, Williams KJ, Feldman M, Aviram M, Shah N, Jarett L, Poncz M, Cines DB, Higazi AAR. Platelet factor 4 binds to low-density lipoprotein receptors and disrupts the endocytic itinerary, resulting in retention of low-density lipoprotein on the cell surface. Blood 99:3613-3622, 2002.

Shaul PW. Endothelial nitric oxide synthase, caveolae and the development of atherosclerosis. J Physiol (Lond) 547:21-33, 2003.

Slungaard A, Key NS. Platelet factor 4 stimulates thrombomodulin protein C-activating cofactor activity. A structure-function analysis. J Biol Chem 269:25549-25556,1994.

Slungaard A, Fernandez JA, Griffin JH, Key NS, Long JR, Piegors DJ, Lentz SR. Platelet factor 4 enhances generation of activated protein C in vitro and in vivo. Blood 102: 146-151, 2003.

Srinivasan AF, Rice L, Bartholomew JR, Rangaswamy C, La Perna L, Thompson JE, Murphy S, Baker KR. Warfarin-induced skin necrosis and venous limb gangrene in the setting of heparin-induced thrombocytopenia. Arch Intern Med 164:66-70, 2004.

Stern D, Nawroth P, Marcum J, Handley D, Kisiel W, Rosenberg R, Stern K. Interaction of antithrombin III with bovine aortic segments. Role of heparin in binding and enhanced anticoagulant activity. J Clin Invest 75:272-279, 1985.

Strieter RM, Burdick MD, Mestas J, Gomperts B, Keane MP, Belperio JA. Cancer CXC chemokine networks and tumour angiogenesis. Eur J Cancer 42:768-778, 2006.

Suvarna S, Rauova L, McCracken EKE, Goss CM, Sachais BS, McKenzie SE, Reilly MP, Gunn MD, Cines DB, Poncz M, Arepally G. PF4/heparin complexes are T cell-dependent antigens. Blood 106:929-931, 2005.

Talusan P, Bedri S, Yang S, Kattapuram T, Silva N, Roughley PJ, Stone JR. Analysis of intimal proteoglycans in atherosclerosis-prone and atherosclerosis-resistant human arteries by mass spectrometry. Mol Cell Proteomics 4:1350-1357, 2005.

Tinckam KJ, Chandraker A. Mechanisms and role of HLA and non-HLA alloantibo-dies. Clin J Am Soc Nephrol 1:404-414, 2006.

Tournamille C, Van Kim CL, Gane P, Blanchard D, Proudfoot AE, Cartron JP, Colin Y. Close association of the first and fourth extracellular domains of the Duffy antigen/ receptor for chemokines by a disulfide bond is required for ligand binding. J Biol Chem 272:16274-16280, 1997.

Trikalinos TA, Karassa FB, Ioannidis JP. Meta-analysis of the association between low-affinity Fcg receptor gene polymorphisms and hematologic and autoimmune disease. Blood 98:1634-1635, 2001.

Van de Wouwer M, Collen D, Conway EM. Thrombomodulin-protein C-EPCR system: integrated to regulate coagulation and inflammation. Arterioscler Thromb Vasc Biol 24:1374-1383, 2004.

Visentin GP, Ford SE, Scott JP, Aster RH. Antibodies from patients with heparin-induced thrombocytopenia/thrombosis are specific for platelet factor 4 complexed with heparin or bound to endothelial cells. J Clin Invest 93:81-88, 1994.

Visentin GP, Malik M, Cyganiak KA, Aster RH. Patients treated with unfractionated heparin during open heart surgery are at high risk to form antibodies reactive with heparin:platelet factor 4 complexes. J Lab Clin Med 128:376-383, 1996.

Warkentin TE, Elavathil LJ, Hayward CPM, Johnston MA, Russett JI, Kelton JG. The pathogenesis of venous limb gangrene complicating heparin-induced thrombocyto-penia. Am J Hematol 127:804-812, 1997.

Williams RT, Damaraju LV, Mascelli MA, Barnathan ES, Califf RM, Simoons ML, Deliargyris EN, Sane DC. Anti-platelet factor 4/heparin antibodies: an independent predictor of 30-day myocardial infarction after acute coronary ischemic syndromes. Circulation 107:2307-2312, 2003.

Wu VY, Cohen MP. Platelet factor 4 binding to glomerular microvascular matrix. Biochim Biophys Acta 797:76-82, 1984.

Yahalom J, Eldor A, Fuks Z, Vlodavsky I. Degradation of sulfated proteoglycans in the subendothelial extracellular matrix by human platelet heparitinase. J Clin Invest 74: 1842-1849, 1984.

Yamaguchi K, Ogawa K, Katsube T, Shimao K, Konno S, Shimakawa T, Yoshimatsu K, Naritaka Y, Yagawa H, Hirose K. Platelet factor 4 gene transfection into tumor cells inhibits angiogenesis, tumor growth and metastasis. Anticancer Res 25:847-851, 2005.

Yu G, Rux AH, Ma P, Bdeir K, Sachais BS. Endothelial expression of E-selectin is induced by the platelet-specific chemokine platelet factor 4 through LRP in an NF-k B-dependent manner. Blood 105:3545-3551, 2005.

10 Ways To Fight Off Cancer

10 Ways To Fight Off Cancer

Learning About 10 Ways Fight Off Cancer Can Have Amazing Benefits For Your Life The Best Tips On How To Keep This Killer At Bay Discovering that you or a loved one has cancer can be utterly terrifying. All the same, once you comprehend the causes of cancer and learn how to reverse those causes, you or your loved one may have more than a fighting chance of beating out cancer.

Get My Free Ebook


Post a comment